Loading page
Loading page
Loading substance route
TMA-2 is reported to be highly unpredictable and dose-sensitive, with a narrow margin between psychoactive and toxic doses. Anecdotal reports indicate variable effects including body load, nausea, and overstimulation.
TMA-2 is considered to have extremely low addiction potential due to its psychedelic nature. It is not habit-forming and the desire to use it can actually decrease with repeated use, making it largely self-regulating.
Human toxic dose is unknown. Dr. Shulgin noted that there is only a small margin between psychoactive and toxic doses. In rats, doses of 120 mg/kg were associated with fatal toxic effects.
| Species | Route | Value |
|---|---|---|
| mouse | unspecified | 180 mg/kg |
High doses in rats caused bradycardia and hypothermia; in humans, vasoconstriction and increased blood pressure have been reported at higher doses, though human data remains extremely limited.
Mental health risks are assumed to be similar to other hallucinogens. Psychedelic-crisis management is appropriate for acute anxiety and panic reactions. More severe psychotic reactions are possible, particularly in individuals with a family history of schizophrenia or early onset mental illness, as psychedelics have been known to trigger latent psychological conditions.
Toxicity studies in rats showed that doses of 80 mg/kg induced frequent clonic convulsions. Given the reported narrow margin between active and toxic doses, seizure risk may be elevated at higher dosages. Individuals with seizure or convulsive disorders are advised to exercise particular caution.
TMA-2 was first synthesized by Hungarian chemist Viktor Bruckner in 1933, but its psychoactive properties remained unrecognized for nearly three decades. Alexander Shulgin independently synthesized the compound in 1962 and conducted the first documented self-experiments to evaluate its effects. His…
UN Convention on Psychotropic Substances 1971 (Schedule I)
EU Council Decision (December 2003) - requiring member states to implement control measures within 90 days
Prohibited under the Suchtmittelgesetz (Narcotics Act). Possession, production, and sale are illegal.
Listed as 2,4,5-trimethoxyamphetamine in Schedule III of the Controlled Drugs and Substances Act. Possession and sale are prohibited.
Controlled under Anlage I of the Betäubungsmittelgesetz (Narcotics Act) since October 10, 1999. Manufacturing, possession, import, export, purchase, sale, procurement, and dispensing without a license are illegal.
Controlled as a positional isomer of TMA (a UN-listed substance) under the Misuse of Drugs Act, similar to UK scheduling.
Control measures enacted in January 2005 alongside 2C-I, 2C-T-2, and 2C-T-7.
Placed into Class I (most restrictive category) as of March 16, 2004.
Classified as a controlled drug under Turkish law. Possession, production, supply, and import are prohibited.
Controlled as a positional isomer of TMA, which is explicitly listed as a Schedule I hallucinogen under the Controlled Substances Act. Manufacturing, possession, and distribution are prohibited.
Added to the list of illegal psychotropic substances on November 8, 2004.
Classified as a controlled substance under Finnish drug legislation.
Became a controlled substance on February 18, 2003.
Added to Tabella I (list of prohibited plants and substances) by Ministry of Health decree on January 11, 2005.
Added to Grade 2 (corresponding to Schedule II of the 1971 UN Convention on Psychotropic Substances) in October 2009.
Specifically named as a controlled substance under Verzeichnis D of Swiss controlled substances legislation.
Controlled as a Class A drug under the Misuse of Drugs Act 1971. Covered by the generic phenethylamine definition as a positional isomer of the UN-controlled drug TMA. Class A classification carries the most severe penalties.
20 sources cited